Thank you for this great summary. Note that FES PET is actually recommended in NCCN guidelines for Stage 4 ILC. Generally we need better monitoring for early stages to prevent recurrence being Stage 4. Do we know if ILC reoccurs at same rate as IDC? Thank you for pointing out it reoccurs later.
Thanks for this helpful update and explanation. I’m a BC survivor with the “unicorn” dx (ILC and TNBC) which led me to get 5 MO opinions before making my treatment decisions. I follow the research and am so happy to see more studies in ILC (as well as in TNBC). You are a terrific resource!
What about people with both ductal and lobular tumors? I had a second opinion after my double mastectomy and they repeated the pathology at that time, discovering areas a well- differentiated ILC near my initial tumor and some area of LCIS in the other breast that were not seen by the first pathologist. If it matters, I also have a BRCA2 pathogenic variant ( the reason for the DMX).
There is so much detailed knowledge now about the different breast cancer subtypes, yet treatment often still seems to be based on the broader category. My hope is that we’ll eventually see more individualized protocols and less overtreatment where it’s safe to do so.
Thank you for sharing this. Those of us with ILC often feel left out of the conversation. I hope there will be more and more research on ILC so that treatment can be more specific and not just carried out as if ILC were the same as ductal
Thank u for this!!!! Strangely my ILC is pleomorphic with low KI 67 (9%) and wonder if other parts of tumor have more aggressiveness….
Any newish news on AI differences for Lobular?
Thank you so much for your fabulous work.
Thank you for this information!
Thank you for this great summary. Note that FES PET is actually recommended in NCCN guidelines for Stage 4 ILC. Generally we need better monitoring for early stages to prevent recurrence being Stage 4. Do we know if ILC reoccurs at same rate as IDC? Thank you for pointing out it reoccurs later.
Thanks for this helpful update and explanation. I’m a BC survivor with the “unicorn” dx (ILC and TNBC) which led me to get 5 MO opinions before making my treatment decisions. I follow the research and am so happy to see more studies in ILC (as well as in TNBC). You are a terrific resource!
What about people with both ductal and lobular tumors? I had a second opinion after my double mastectomy and they repeated the pathology at that time, discovering areas a well- differentiated ILC near my initial tumor and some area of LCIS in the other breast that were not seen by the first pathologist. If it matters, I also have a BRCA2 pathogenic variant ( the reason for the DMX).
There is so much detailed knowledge now about the different breast cancer subtypes, yet treatment often still seems to be based on the broader category. My hope is that we’ll eventually see more individualized protocols and less overtreatment where it’s safe to do so.
Thank you for sharing this. Those of us with ILC often feel left out of the conversation. I hope there will be more and more research on ILC so that treatment can be more specific and not just carried out as if ILC were the same as ductal